Analogue peptides for the immunotherapy of human acute myeloid leukemia

Cancer Immunology, Immunotherapy

Volumn 64, Issue 11, 2015, Pages 1357-1367

  Hofmann, Susanne ^a   Mead, Andrew ^b   Malinovskis, Aleksandrs ^b   Hardwick, Nicola R ^c,d   Guinn, Barbara ann ^b,d,e  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adult acute myeloid leukemia; Analogue peptides; Clinical trials; Heteroclitic peptides; NPM1; PASD1

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMA 901; IMMUNOLOGICAL ADJUVANT; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; SELF ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE; HLA ANTIGEN CLASS 2; LYMPHOCYTE ANTIGEN RECEPTOR; NUCLEAR PROTEIN; NUCLEOPHOSMIN; SUBUNIT VACCINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG BINDING SITE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; REVIEW; TUMOR CELL DESTRUCTION; CLASSIFICATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; PHYSIOLOGY; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, MYELOID, ACUTE; NUCLEAR PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT;

EID: 84945174963     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1762-9     Document Type: Review

References (100)

1. Guinn BA, Mohamedali A, Thomas NS, Mills KI (2007) Immunotherapy of myeloid leukaemia. Cancer Immunol Immunother 56:943–957
2. Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, Galea-Lauri J et al (2006) An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 55:1017–1024
3. Cheuk AT, Chan L, Czepulkowski B, Berger SA, Yagita H, Okumura K et al (2006) Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother 55:68–75
4. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
5. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R et al (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810–11813
6. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
7. Khan G, Brooks SE, Mills KI, Guinn BA (2015) Expression of the cancer–testis antigen, PASD1, in ovarian cancer. Biomark Cancer 7:31–38
8. Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ et al (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16:2238–2242
9. Van Driessche A, Berneman ZN, Van Tendeloo VF (2012) Active specific immunotherapy targeting the Wilms’ tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 17:250–259
10. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S et al (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun. 335:1293–1304
11. Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J et al (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100:3835–3837
12. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI et al (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709–2716
13. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405–1412
14. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108
15. Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D et al (2011) “Wilms Tumor Protein 1” (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother 34:85–91
16. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111:236–242
17. Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A et al (2014) Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 164:366–375
18. + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113:2245–2255
19. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al (2003) Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 111:639–647
20. Qazilbash MH, Weider E, Rios R, Lu S, Kant S, Giralt S, Estey E, Thall P, de Lima M, Couriel D, Champlin RE, Komanduri K, Molldrem JJ (2004) Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 104: abstract 259
21. + CTL priming by exact peptide epitopes in incomplete Freund’s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 179:5033–5040
22. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C et al (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13:6386–6395
23. Wells JW, Cowled CJ, Farzaneh F, Noble A (2008) Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 181:3422–3431
24. Kochenderfer JN, Simpson JL, Chien CD, Gress RE (2007) Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood 110:450–460
25. Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M et al (2007) Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 98:1965–1968
26. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414
27. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739–746
28. Lovgren T, Baumgaertner P, Wieckowski S, Devevre E, Guillaume P, Luescher I et al (2012) Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother 61:817–826
29. Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894–1907
30. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261
31. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648
32. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L et al (2013) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Investig Dermatol 133:1610–1619
33. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F et al (2001) Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94:243–251
34. Keskinen P, Ronni T, Matikainen S, Lehtonen A, Julkunen I (1997) Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. Immunology 91:421–429
35. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD et al (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108:618–621
36. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157
37. Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E et al (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA 89:416–420
38. Warnock MG, Goodacre JA (1997) Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br J Rheumatol 36:1144–1150
39. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O et al (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906
40. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS et al (2003) The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102:3287–3294
41. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL (2005) Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 115:333–336
42. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2 m) HLA-A2.1 monochain transgenic H-2Db beta2 m double knockout mice. J Exp Med 185:2043–2051
43. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A et al (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433
44. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM et al (2005) Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 201:1243–1255
45. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB et al (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23:516–526
46. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ (1996) Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol. 156:3308–3314
47. Harndahl M, Rasmussen M, Roder G, Dalgaard Pedersen I, Sorensen M, Nielsen M et al (2012) Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42:1405–1416
48. Mason D (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19:395–404
49. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE (1993) Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. J Immunol 151:5000–5010
50. Bakker AB, van der Burg SH, Huijbens RJ, Drijfhout JW, Melief CJ, Adema GJ et al (1997) Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 70:302–309
51. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA et al (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539–2548
52. Frankild S, de Boer RJ, Lund O, Nielsen M, Kesmir C (2008) Amino acid similarity accounts for T cell cross-reactivity and for “holes” in the T cell repertoire. PLoS ONE 3:e1831
53. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG (2006) Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood 108:3865–3870
54. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA (2005) Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 90:1324–1332
55. + T cell responses against naturally processed peptide. Cancer Immunity. 13:16
56. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y et al (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 165:948–955
57. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A et al (2002) Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51:614–620
58. Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V et al (2006) Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 20:2025–2033
59. + T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 13:4547–4555
60. Meng WS, Butterfield LH (2002) Rational design of peptide-based tumor vaccines. Pharm Res 19:926–932
61. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA et al (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809–8814
62. Stauss HJ, Morris EC (2013) Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 20:1029–1032
63. Bae J, Martinson JA, Klingemann HG (2004) Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. Clin Cancer Res 10:7043–7052
64. Bae J, Martinson JA, Klingemann HG (2004) Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol 227:38–50
65. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071–3079
66. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM et al (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198–2203
67. Ohminami H, Yasukawa M, Fujita S (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95:286–293
68. Smithgall M, Misher L, Spies G, Cheever MA, Gaiger A (2001) Identification of a novel WT1 HLA-A*0201-restricted CTL epitope using whole gene in vitro priming [abstract]. American Society of Hematology meeting, 8–11 Dec 2001, Orlando, FL
69. + T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transpl 43:399–410
70. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113:6541–6548
71. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al (2004) Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101:13885–13890
72. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al (2010) Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 116:171–179
73. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729
74. Narayan S, Choyce A, Fernando GJ, Leggatt GR (2007) Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity. Eur J Immunol 37:406–415
75. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E et al (2014) PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 124:2246–2259
76. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918
77. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P et al (2007) Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 92:519–532
78. Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S et al (2008) Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia 22:1234–1240
79. Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Gotz M et al (2012) Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 120:1282–1289
80. Greiner J, Schneider V, Schmitt M, Gotz M, Dohner K, Wiesneth M et al (2013) Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). Blood 122:1087–1088
81. Hofmann S, Gotz M, Schneider V, Guillaume P, Bunjes D, Dohner H et al (2013) Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol 31:e44–e47
82. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M et al (2008) DNA vaccination induces Wt1-specific T-cell responses with potential clinical relevance. Blood 112:2956–2964
83. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S et al (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9:1413–1417
84. Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M et al (2006) Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 55:850–860
85. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
86. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
87. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
88. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577–581
89. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189–2199
90. Romano E, Michielin O, Voelter V, Laurent J, Bichat H, Stravodimou A et al (2014) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 12:97
91. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127
92. Maccalli C, De Maria R (2015) Cancer stem cells: perspectives for therapeutic targeting. Cancer Immunol Immunother 64:91–97
93. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050
94. Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A et al (2009) Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. J Immunother 32:613–621
95. + T cells in melanoma patients. J Immunother 31:781–791
96. Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P (2015) Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother 64:99–104
97. Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T et al (2008) A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 22:1613–1616
98. + T-cell responses using overlapping peptide pools. Cancer Immunol Immunother 61:1953–1963
99. Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ et al (2014) New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother 63:1093–1103
100. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, van der Burg SH et al (2010) Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 70:8339–8346